These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11146571)

  • 1. Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders.
    Yoon SY; Tefferi A; Li CY
    Haematologica; 2001 Jan; 86(1):52-7. PubMed ID: 11146571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders.
    Yoon SY; Li CY; Lloyd RV; Tefferi A
    Int J Hematol; 2000 Oct; 72(3):337-42. PubMed ID: 11185990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.
    Keith T; Araki Y; Ohyagi M; Hasegawa M; Yamamoto K; Kurata M; Nakagawa Y; Suzuki K; Kitagawa M
    Br J Haematol; 2007 May; 137(3):206-15. PubMed ID: 17408459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand factor is the most reliable immunohistochemical marker for megakaryocytes of myelodysplastic syndrome and chronic myeloproliferative disorders.
    Chuang SS; Jung YC; Li CY
    Am J Clin Pathol; 2000 Apr; 113(4):506-11. PubMed ID: 10761451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
    Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
    Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
    Tauro S; Hepburn MD; Bowen DT; Pippard MJ
    Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [LAT (linker for activation of T cells): a useful marker for megakaryocyte evaluation on bone marrow biopsies].
    Ungari M; Pellegrini W; Borlenghi E; Marocolo D; Ubiali A; Agazzi C; Pich A; Franco V; Facchetti F
    Pathologica; 2002 Dec; 94(6):325-30. PubMed ID: 12540999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
    Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
    Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
    Bock O
    Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The implications of the biological indices examination of bone marrow cells in myelodysplastic syndromes].
    Zhang F; Hao Y; Pang W
    Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):528-32. PubMed ID: 11769678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral T-cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor.
    Kikukawa M; Umahara T; Kikawada M; Kanaya K; Sakurai H; Shin K; Mori M; Iwamoto T
    Geriatr Gerontol Int; 2009 Dec; 9(4):395-8. PubMed ID: 20002760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
    Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
    Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of forced expression of basic fibroblast growth factor in human bone marrow-derived mesenchymal stromal cells.
    Go MJ; Takenaka C; Ohgushi H
    J Biochem; 2007 Dec; 142(6):741-8. PubMed ID: 17956905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
    J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
    Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
    Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.